Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo
about
Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cellsProto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatmentRLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancerProtein kinase A and B-Raf mediate extracellular signal-regulated kinase activation by thyrotropincAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4.Update: the status of clinical trials with kinase inhibitors in thyroid cancerThe PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.Lessons from mouse models of thyroid cancer.Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71.NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma.RAS Interaction with PI3K: More Than Just Another Effector PathwayEvaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinomaCross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.Molecular pathogenesis and mechanisms of thyroid cancerSynergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.Feedback regulations of miR-21 and MAPKs via Pdcd4 and Spry1 are involved in arsenite-induced cell malignant transformationInhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells.Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouseMolecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis.Modulation of sodium iodide symporter in thyroid cancerMedullary and papillary carcinoma of the thyroid gland occurring as a collision tumor with lymph node metastasis: A case report.Modeling follicular thyroid cancer for future therapiesClinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer.Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAFMouse models of follicular and papillary thyroid cancer progression.Association between the KRAS Gene Polymorphisms and Papillary Thyroid Carcinoma in a Chinese Han Population.Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.Mouse models of thyroid cancer: A 2015 update.FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinomaEvolving approaches to patients with advanced differentiated thyroid cancerThyroid-specific ablation of the Carney complex gene, PRKAR1A, results in hyperthyroidism and follicular thyroid cancer.Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss.Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer.The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutationsClinicopathological and molecular histochemical review of skull base metastasis from differentiated thyroid carcinomaObatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosisImmune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by HrasG12V and Pten Loss.Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.Thyroid cancer in 2010: a roadmap for targeted therapies.
P2860
Q24318292-890B157A-B54C-46D4-93D5-FCBA8BB93A84Q24635291-0F9825DD-DE0B-40CC-8EA7-F8C2D6CE4169Q28482104-9C518A0B-5398-4717-826B-8BC68AA03775Q28569443-AF8D05E0-AE05-403C-AC1E-CAD9DAEAB544Q30431658-E80CD253-EBE4-48A5-A1A5-A3B36D0CD691Q33570056-77AADB85-A75D-48F3-A46E-1C7F7FBCD787Q33770769-1B010882-6318-4750-BF4C-9FDD0B02F396Q33819911-30683FC6-3408-4425-A1A6-DD843E534AB0Q33914771-02E2283B-E473-4623-A812-00C72FD27121Q33931406-42895C10-89A2-4881-A88B-39DADBAB0B79Q34202692-2EFF986E-7FC8-4750-BA50-F8931681D848Q34226772-91C2B4FD-FA12-43DA-B2D8-4F10E456F8F8Q34259396-166EF4F1-7E98-4F38-8EA4-B05E9555D786Q34329018-00C16EA7-1CEE-4199-BBD2-7AAB7832B855Q34528284-0222E9A2-5488-4991-A4B4-DC15DD366DEFQ34613149-B57C2B0A-C2C3-402E-B3A4-BE3DA4E223F5Q34782086-A3C362A0-C44A-4AD6-B995-BFA7D152A90AQ35022217-F02463CF-EC43-42DF-B0B9-058F66319F23Q35116008-EB331FD2-8364-4AFE-8EC6-977E33166976Q35132940-03A16F2B-CC74-4181-960E-7B28D41CAA38Q35690173-E7348E25-EC67-43AB-B654-7D0E1594302AQ35772255-41291214-8AD8-4129-B879-F083374371FCQ35832908-BADEC4E2-1A62-4662-851E-F5EB6F6B7AB9Q35906046-E1A7E9B8-F5FE-4977-B431-F3406C747B7AQ35914464-BAE6DF7B-4B9A-4D0D-9FD4-BFA517AC4153Q35971896-1E07FE6E-D065-45D8-B3DA-933AFD41FC53Q36229033-2664BA16-4EF0-4571-9E36-3BA47F0B99EBQ36293901-47710C1A-2818-4A49-83CB-29AA56BC94D4Q36405539-A4ACFAB1-1261-45F7-9FF4-FABAF6BF57F3Q36799818-8B9B4369-C9FF-4E8C-A843-DFE61430F9C6Q36864736-766AD1BE-36F6-4C83-B3F4-5CC1F9819C52Q36887299-FFECE76C-BCB0-467C-93B2-1C848C2FEF4AQ36917756-B3A22C38-36B6-4CBB-B03D-58C9C0A46FD3Q37110973-7BE220E8-6EE6-4D3E-84ED-50F388120102Q37199459-37E6AF60-7D26-4834-94BE-5C0A54D63129Q37269653-4E8A8A91-7F30-4826-9CBB-ECD2928FF1B7Q37376300-81AFD1DC-88AF-4099-ADA8-20AE5507FDC2Q37486166-D9B08C8D-B9EC-4678-931A-901C5B172823Q37767709-8B2697D4-7807-41BC-94FB-A386D1937F3BQ37832117-87952411-87A8-4A76-808F-C934FB2A71AD
P2860
Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Oncogenic Kras requires simult ...... yroid epithelial cells in vivo
@ast
Oncogenic Kras requires simult ...... yroid epithelial cells in vivo
@en
Oncogenic Kras requires simult ...... yroid epithelial cells in vivo
@nl
type
label
Oncogenic Kras requires simult ...... yroid epithelial cells in vivo
@ast
Oncogenic Kras requires simult ...... yroid epithelial cells in vivo
@en
Oncogenic Kras requires simult ...... yroid epithelial cells in vivo
@nl
prefLabel
Oncogenic Kras requires simult ...... yroid epithelial cells in vivo
@ast
Oncogenic Kras requires simult ...... yroid epithelial cells in vivo
@en
Oncogenic Kras requires simult ...... yroid epithelial cells in vivo
@nl
P2093
P2860
P1433
P1476
Oncogenic Kras requires simult ...... yroid epithelial cells in vivo
@en
P2093
Antonio Di Cristofano
Kelly A Miller
Kristen Baker
Nicole Yeager
Samuel Refetoff
Xiao-Hui Liao
P2860
P304
P356
10.1158/0008-5472.CAN-09-0024
P407
P577
2009-04-07T00:00:00Z